Immuno-Biological Laboratories , Ltd. Profit Margin

Immuno-Biological Laboratories , Ltd. posts a profit margin of 34.12% as of June 2026. That compares with 27.17% in the prior-year period — up 25.6% year over year. That is above the Healthcare sector average of 9.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Immuno-Biological Laboratories , Ltd.'s profit margin was 27.17%. The latest reading is 34.12% — a 25.6% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.48% is typical. Immuno-Biological Laboratories , Ltd.'s 34.12% is higher that level. That is roughly 259.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Immuno-Biological Laboratories , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 34.12% as of June 2026; use YoY and peer views to separate noise from signal.

Context for 4570.T's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.48%), and (3) consistency with growth and profitability. This page covers the first two; Immuno-Biological Laboratories , Ltd.'s other metric pages and overview cover the third.